US20240368292
2024-11-07
Chemistry; metallurgy
C07K16/2866
The patent application focuses on compositions and methods related to antigen binding proteins that specifically target the human ST2 receptor, including fully human antibodies. These proteins are designed to bind with high affinity to ST2, effectively blocking the interaction with interleukin-33 (IL-33) and consequently reducing IL-33-mediated pro-inflammatory signaling. The application outlines the development of these antibodies, their genetic encoding, and their potential therapeutic applications, particularly in the treatment of autoimmune and inflammatory disorders.
ST2 is a receptor for IL-33, a cytokine involved in inflammatory processes. It exists in two forms: a soluble variant and a membrane-spanning form that mediates cellular responses. The membrane form is found on various immune cells implicated in inflammation, such as T helper cells and mast cells. IL-33 binding to ST2 leads to pro-inflammatory signaling, contributing to conditions like asthma, rheumatoid arthritis, and inflammatory bowel disease. The IL-33/ST2 pathway is linked to chronic inflammation, making it a target for therapeutic intervention.
The application presents evidence linking the IL-33/ST2 pathway to various human diseases through genetic studies and observed elevated levels of IL-33 and soluble ST2 in patients with inflammatory conditions. Genetic polymorphisms in IL-33 or ST2 have been associated with increased risk of diseases such as asthma and atopic dermatitis. The pathway's role in promoting harmful inflammation underscores its potential as a target for new treatments.
The invention provides anti-ST2 antigen binding proteins with commercial production potential for therapeutic use. These proteins are designed to treat diseases associated with the IL-33/ST2 axis by binding ST2 with high affinity and blocking IL-33 interaction. This approach aims to reduce inflammation by preventing the activation of pro-inflammatory pathways mediated by IL-33.
The invention describes specific sequences for light and heavy chain variable domains that form the basis of these antigen binding proteins. These sequences exhibit at least 90% identity to specified amino acid sequences, ensuring high specificity and efficacy. The application details preferred combinations of these sequences for optimal therapeutic effect, providing a foundation for developing effective treatments targeting the IL-33/ST2 axis in various inflammatory diseases.